Worldwide Cervical Cancer Screening Market to 2026 – Impact of COVID-19 – ResearchAndMarkets.com | Coronavirus
DUBLIN–(BUSINESS WIRE)–Sep 28, 2020–
The “Cervical Cancer Screening Market, Patients, Mortality Global Forecast by Tests Type (Pap Smear, HPV DNA, VIA), 19 Countries Analysis” report has been added to ResearchAndMarkets.com‘s offering.
Globally, cervical cancer is the most appearing cancer in women. Cervical cancer is most frequently diagnosed in women between the age of 35 and 44 with the average age of diagnosis being 50. In 2019, an estimated 283.15 million women were diagnosed with cervical cancer worldwide, and about 311,000 women died from the disease in 2018. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences.
There are three types of screening for identifying cervical cancer: Pap Smear Tests, Human Papillomavirus Virus (HPV) Tests and Visual Inspection with Acetic Acid (VIA) Tests. These screenings are a key factor anticipated to boost the number of screening tests over the forecast period. Effective primary (HPV vaccination) approach (testing and treating precancerous lesions) will prevent most cervical cancer cases. According to this report, the Cervical Cancer Screening Market is expected to be USD 16.5 Billion by 2026.
This report provides 19 Countries’ cervical cancer market analysis & forecast with numbers of screening & Mortality. In the United States, the medical community has made great strides in preventing and controlling cervical cancer. The reasons that influence world market dominance are the presence of technological advancements in terms of new diagnostic equipment, diagnostic procedures, favourable government policies related to reimbursement and screening techniques are expected to have a positive impact on the market. Cervical cancer is one of the leading causes of female cancer deaths in low- and middle-income countries.
COVID-19 impacts Global Cervical Cancer Screening Industry
The cervical cancer screening declined to meager numbers due to the coronavirus pandemic. Most non-urgent cervical cancer appointments have been cancelled in the wake of COVID-19. However, things started moving in the last two quarters, but they will not return to pre-COVID numbers this year. Preventive measures should be put in place during the efforts of providing cervical cancer screening as directed by the health authorities. Read the complete analysis on how COVID-19 has affected the cervical cancer screening market and its future.
According to this report Cervical Cancer Market, Patients, Mortality Global Forecast by Tests (Pap Smear, HPV DNA, VIA), 19 Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia):
Cervical Cancer Screening Market & Population – the report studies all 3 types of Tests
- Pap Smear Tests Market
- HPV DNA Tests Market
- VIA Tests Market
Cervical Cancer Mortality Population
In this section number of deaths by cervical cancer in all the 19 countries from 2014 to 2020 has been captured. The report gives complete insights of Market, Screened Population & Mortality of 19 countries, which provides a general idea of worldwide countries analysis of Global Cervical Cancer Screening Industry.
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Global Cervical Cancer Test (Screening) Population
4.1 Asia
4.2 Europe
4.3 North America
4.4 Rest of World
5. Global Cervical Cancer Test (Screening) Market
5.1 Pap Smear Test (Screening)
5.2 HPV DNA Test (Screening)
6. By Region – Global Cervical Cancer Test (Screening) Market Analysis
6.1 Asia
6.2 Europe
6.3 North America
6.4 Rest of World
7. Population Share – Global Cervical Cancer Test (Screening)
7.1 By Region
7.2 By Countries
8. Market Share – Global Cervical Cancer Test (Screening)
8.1 Region – Cervical Cancer Test (Screening)
8.2 Countries – Cervical Cancer Test (Screening)
8.3 Countries – Pap Smear Test (Screening)
8.4 Countries – HPV DNA Test (Screening)
8.5 Countries – VIA Test (Screening)
9. United Kingdom – Cervical Cancer Test Analysis
9.1 United Kingdom Cervical Cancer Test (Screening) Population & Forecast
9.1.1 United Kingdom Pap Smear Test Population
9.1.2 United Kingdom HPV DNA Test Population
9.2 United Kingdom Cervical Cancer Deaths
9.3 United kingdom Cervical Cancer Test (Screening) Market & Forecast
9.3.1 United Kingdom Pap Smear Test Market
9.3.2 United Kingdom HPV DNA Test Market
10. France – Cervical Cancer Test Analysis
11. Germany – Cervical Cancer Test Analysis
12. Italy – Cervical Cancer Test Analysis
13. Spain – Cervical Cancer Test Analysis
14. Sweden – Cervical Cancer Test Analysis
15. Switzerland – Cervical Cancer Test Analysis
16. Norway – Cervical Cancer Test Analysis
17. Netherlands – Cervical Cancer Test Analysis
18. United States – Cervical Cancer Test Analysis
19. Canada – Cervical Cancer Test Analysis
20. Japan – Cervical Cancer Test Analysis
21. South Korea – Cervical Cancer Tests Analysis
22. Singapore – Cervical Cancer Tests Analysis
23. Malaysia – Cervical Cancer Test Analysis
24. India – Cervical Cancer Test Analysis
25. China – Cervical Cancer Test Analysis
26. Thailand – Cervical Cancer Test Analysis
27. Indonesia – Cervical Cancer Test Analysis
28. Rest of World – Cervical Cancer Test Analysis
29. Growth Drivers
29.1 Introduction of Low Cost VIA Test
29.1.1 Countries Offering VIA Test via National Programs
29.1.2 Countries Offering VIA Test via Pilot Programs
29.2 Worldwide High Prevalence of HPV Infected Patients
29.3 Rising Number of Incidence of Cervical Cancer in United Kingdom
29.4 Worldwide Rising Incidence of Teenage Sexual Cases
30. Challenges
30.1 Lack of Appropriate Healthcare Infrastructure
30.2 Introduction of HPV Vaccination Programs Worldwide
For more information about this report visit https://www.researchandmarkets.com/r/oqojmq
View source version on businesswire.com:https://www.businesswire.com/news/home/20200928005508/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH ONCOLOGY MEDICAL DEVICES
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 09/28/2020 10:12 AM/DISC: 09/28/2020 10:12 AM
